Abel E. Vasquez
Santiago, RM 8580745, Chile
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Lactococcus lactis as a New Strategy for Oral Vaccination: Current Insights and Future Perspectives.
Lactococcus lactis as a New Strategy for Oral Vaccination: Current Insights and Future Perspectives.
Journal: Pharmaceutics
Published: November 25, 2025
Predictive analysis of B-cell antigenic epitopes in phospholipase D toxins from Loxosceles spiders.
Journal: Toxicon: X
Published: January 10, 2025
Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac.
Journal: Vaccines
Published: February 08, 2024
Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile.
Journal: Frontiers in public health
Published: May 25, 2023
Surface immunogenic protein from Streptococcus agalactiae and Fissurella latimarginata hemocyanin are TLR4 ligands and activate MyD88- and TRIF dependent signaling pathways.
Journal: Frontiers in immunology
Published: March 14, 2023
Protein-Based Adjuvants for Vaccines as Immunomodulators of the Innate and Adaptive Immune Response: Current Knowledge, Challenges, and Future Opportunities.
Journal: Pharmaceutics
Published: June 21, 2022
Validation of a Methodology for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Saliva by Real-Time Reverse Transcriptase-PCR.
Journal: Frontiers in public health
Published: July 18, 2021
Host Components That Modulate the Disease Caused by hMPV.
Journal: Viruses
Published: December 04, 2020
Development and analytical validation of real-time PCR for the detection of Streptococcus agalactiae in pregnant women.
Journal: BMC pregnancy and childbirth
Published: March 04, 2020
Mucosal Vaccination with Lactococcus lactis-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B Streptococcus in a Murine Model.
Journal: Vaccines
Published: February 18, 2020
Surface Immunogenic Protein of Streptococcus Group B is an Agonist of Toll-Like Receptors 2 and 4 and a Potential Immune Adjuvant.
Journal: Vaccines
Published: November 07, 2019
BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design.
Journal: Frontiers in immunology
Published: October 10, 2019
Last Updated: 09/26/2026